Shares of Entrada Therapeutics (NASDAQ: TRDA) tanked more than 30% in pre-market trading on Tuesday after the U.S. FDA placed a clinical hold on TRDA’s Investigational New Drug Application (IND) for ENTR-601-44 for the potential treatment of Duchenne muscular dystrophy.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
The biopharma company “plans to share additional updates pending further communications with the Agency.”
TRDA stock has risen by more than 40% in the past year.